EP2035038A4 - Compositions et méthodes pour le traitement d'une polykystose rénale - Google Patents

Compositions et méthodes pour le traitement d'une polykystose rénale

Info

Publication number
EP2035038A4
EP2035038A4 EP07760034A EP07760034A EP2035038A4 EP 2035038 A4 EP2035038 A4 EP 2035038A4 EP 07760034 A EP07760034 A EP 07760034A EP 07760034 A EP07760034 A EP 07760034A EP 2035038 A4 EP2035038 A4 EP 2035038A4
Authority
EP
European Patent Office
Prior art keywords
polykystosis
compositions
methods
treating renal
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07760034A
Other languages
German (de)
English (en)
Other versions
EP2035038A2 (fr
Inventor
Xiaogang Li
Rong Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stowers Institute for Medical Research
Original Assignee
Stowers Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stowers Institute for Medical Research filed Critical Stowers Institute for Medical Research
Publication of EP2035038A2 publication Critical patent/EP2035038A2/fr
Publication of EP2035038A4 publication Critical patent/EP2035038A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP07760034A 2006-04-03 2007-04-03 Compositions et méthodes pour le traitement d'une polykystose rénale Withdrawn EP2035038A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74418206P 2006-04-03 2006-04-03
US82587306P 2006-09-15 2006-09-15
PCT/US2007/065869 WO2007118084A2 (fr) 2006-04-03 2007-04-03 Compositions et méthodes pour le traitement d'une polykystose rénale

Publications (2)

Publication Number Publication Date
EP2035038A2 EP2035038A2 (fr) 2009-03-18
EP2035038A4 true EP2035038A4 (fr) 2011-04-06

Family

ID=38581793

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07760034A Withdrawn EP2035038A4 (fr) 2006-04-03 2007-04-03 Compositions et méthodes pour le traitement d'une polykystose rénale

Country Status (4)

Country Link
EP (1) EP2035038A4 (fr)
JP (1) JP2009532495A (fr)
CA (1) CA2648407A1 (fr)
WO (1) WO2007118084A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120122787A1 (en) * 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035601A1 (fr) * 1996-03-26 1997-10-02 The Regents Of The University Of California TRAITEMENT D'UNE MALADIE KYSTIQUE PAR TNF-$g(a)
WO2000037085A1 (fr) * 1998-12-18 2000-06-29 Scios Inc. Traitement d'affections impliquant la formation de kystes
US6638726B1 (en) * 2000-01-06 2003-10-28 Mount Sinai School Of Medicine Of New York University Screening methods for compounds useful in the treatment of polycystic kidney disease
US20040063672A1 (en) * 2002-04-05 2004-04-01 Philip Frost Method for the treatment of polycystic kidney disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101120857B1 (ko) * 2003-06-26 2012-04-12 노파르티스 아게 5원의 헤테로사이클-기재 ｐ38 키나제 억제제
TWI439284B (zh) * 2004-04-09 2014-06-01 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997035601A1 (fr) * 1996-03-26 1997-10-02 The Regents Of The University Of California TRAITEMENT D'UNE MALADIE KYSTIQUE PAR TNF-$g(a)
WO2000037085A1 (fr) * 1998-12-18 2000-06-29 Scios Inc. Traitement d'affections impliquant la formation de kystes
US6638726B1 (en) * 2000-01-06 2003-10-28 Mount Sinai School Of Medicine Of New York University Screening methods for compounds useful in the treatment of polycystic kidney disease
US20040063672A1 (en) * 2002-04-05 2004-04-01 Philip Frost Method for the treatment of polycystic kidney disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FURST DANIEL E ET AL: "Adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: Results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)", JOURNAL OF RHEUMATOLOGY, JOURNAL OF RHEUMATOLOGY PUBLISHING COMPANY, CA, vol. 30, no. 12, 1 December 2003 (2003-12-01), pages 2563 - 2571, XP008128348, ISSN: 0315-162X *
GARDNER K D JR ET AL: "Cytokines in fluids from polycystic kidneys.", KIDNEY INTERNATIONAL APR 1991 LNKD- PUBMED:2051729, vol. 39, no. 4, April 1991 (1991-04-01), pages 718 - 724, XP002623132, ISSN: 0085-2538 *
LEE DUNG-FANG ET AL: "IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway.", CELL 10 AUG 2007 LNKD- PUBMED:17693255, vol. 130, no. 3, 10 August 2007 (2007-08-10), pages 440 - 455, XP002623136, ISSN: 0092-8674 *
LI XIAOGANG ET AL: "A tumor necrosis factor-alpha-mediated pathway promoting autosomal dominant polycystic kidney disease", NATURE MEDICINE, vol. 14, no. 8, August 2008 (2008-08-01), pages 863 - 868, XP002623135, ISSN: 1078-8956 *
MIKULS T R ET AL: "TNF BLOCKADE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: INFLIXIMAB VERSUS ETANERCEPT", EXPERT OPINION ON PHARMACOTHERAPY, ASHLEY, LONDON, UK, vol. 2, no. 1, 1 January 2001 (2001-01-01), pages 75 - 84, XP009066203, ISSN: 1465-6566, DOI: 10.1517/14656566.2.1.75 *
NAKAMURA TSUKASA ET AL: "Increased endothelin and endothelin receptor mRNA expression in polycystic kidneys of cpk mice", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 4, no. 4, 1993, pages 1064 - 1072, XP002623133, ISSN: 1046-6673 *
SHILLINGFORD JONATHAN M ET AL: "The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 4 APR 2006 LNKD- PUBMED:16567633, vol. 103, no. 14, 27 March 2006 (2006-03-27), ONLINE AHEAD OF PRINT, pages 5466 - 5471, XP002623134, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2007118084A2 (fr) 2007-10-18
JP2009532495A (ja) 2009-09-10
CA2648407A1 (fr) 2007-10-18
EP2035038A2 (fr) 2009-03-18
WO2007118084A3 (fr) 2008-10-16

Similar Documents

Publication Publication Date Title
EP1973549A4 (fr) Méthodes et compositions pour l'administration de fer
FR23C1003I2 (fr) Compositions et leurs utilisations pour le traitement de la Sclérose en plaques
EP2021005A4 (fr) Méthodes et composition pour traitement d'une douleur inflammatoire
EP2049151A4 (fr) Méthodes et compositions pour le traitement du cancer
EP2192913A4 (fr) Compositions et procédés pour le traitement d'infestations par demodex
EP2182804A4 (fr) Procédés de traitement d'une dépendance
EP2001484A4 (fr) Méthodes et compositions destinées à traiter l'hypercholestérolémie et l'athérosclérose
EP2111408A4 (fr) Compositions et procédés comprenant des microarn pour traiter une néoplasie
EP2037929A4 (fr) Compositions et procédés pour améliorer l'hyperlipidémie
EP2034906A4 (fr) Compositions et méthodes pour joindre des lumières non unies
EP1796666A4 (fr) Methodes et compositions de traitement de l'hyperlipidemie
EP2341943A4 (fr) Compositions et procédés pour inhiber spécifiquement de l'expression d'un gène par modifications du traitement de l'arnds
EP2166841A4 (fr) Procédés et compositions pour inhiber le facteur d' dème et l'adénylylcyclase
EP2313146A4 (fr) Dispositifs pour le traitement d'un anévrysme vasculaire
EP2297341A4 (fr) Procédés et compositions pour le traitement de la maladie de huntington
EP1940437A4 (fr) Compositions et procedes pour le traitement de bacteries
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
EP1982559A4 (fr) Composition et procédé pour traiter une perte auditive
EP2182810A4 (fr) Compositions et procédés de traitement et de prévention de l'ostéoarthrite
EP2034841A4 (fr) Méthodes et préparations pour le traitement de biofilms
EP2068865A4 (fr) Procédés et compositions pour traitement thérapeutique
EP2134171A4 (fr) Compositions et procédés pour la formation et le remodelage osseux
EP2267217A4 (fr) Composition d'agents de traitement pour textiles
EP2078032A4 (fr) Compositions et procédés pour supprimer la prolifération de l'endomètre
EP2155262A4 (fr) Compositions pour thérapies et imageries ciblées

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081101

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20110307

17Q First examination report despatched

Effective date: 20120702

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121201